Dror Harats - Jan 1, 2023 Form 3 Insider Report for Vascular Biogenics Ltd. (VBLT)

Role
Chief Executive Officer, Director
Signature
/s/ Samuel Backenroth, Attorney-in-Fact
Stock symbol
VBLT
Transactions as of
Jan 1, 2023
Transactions value $
$0
Form type
3
Date filed
1/3/2023, 08:06 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding VBLT Ordinary Shares 1.14M Jan 1, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding VBLT Restricted Stock Units Jan 1, 2023 Ordinary Shares 700K Direct F1
holding VBLT Stock Option (Right to Buy) Jan 1, 2023 Ordinary Shares 148K $2.47 Direct F2
holding VBLT Stock Option (Right to Buy) Jan 1, 2023 Ordinary Shares 223K $2.47 Direct F2
holding VBLT Stock Option (Right to Buy) Jan 1, 2023 Ordinary Shares 60K $3.32 Direct F3
holding VBLT Stock Option (Right to Buy) Jan 1, 2023 Ordinary Shares 30K $3.32 Direct F3
holding VBLT Stock Option (Right to Buy) Jan 1, 2023 Ordinary Shares 45K $3.32 Direct F3
holding VBLT Stock Option (Right to Buy) Jan 1, 2023 Ordinary Shares 45K $3.32 Direct F3
holding VBLT Stock Option (Right to Buy) Jan 1, 2023 Ordinary Shares 75K $5.08 Direct F4
holding VBLT Stock Option (Right to Buy) Jan 1, 2023 Ordinary Shares 80K $5.99 Direct F4
holding VBLT Stock Option (Right to Buy) Jan 1, 2023 Ordinary Shares 240K $1.22 Direct F4
holding VBLT Stock Option (Right to Buy) Jan 1, 2023 Ordinary Shares 240K $1.22 Direct F5
holding VBLT Stock Option (Right to Buy) Jan 1, 2023 Ordinary Shares 240K $1.22 Direct F6
holding VBLT Stock Option (Right to Buy) Jan 1, 2023 Ordinary Shares 240K $2.31 Direct F7
holding VBLT Stock Option (Right to Buy) Jan 1, 2023 Ordinary Shares 160K $2.12 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") granted under the Issuer's Employee Share Ownership and Option Plan (2014) (the "2014 Plan"). Each RSU represents a contingent right to receive one Ordinary Share, par value NIS 0.01, at an exercise price of NIS 0.01, has no expiration date and vests as follows: 75% of the RSUs shall vest on March 31, 2023, with the remaining 25% vesting on August 9, 2024.
F2 These options were granted under the Issuer's Employee Share Ownership and Option Plan (2000) and are fully vested and exercisable.
F3 These options were granted under the Issuer's Employee Share Ownership and Option Plan (2011) and are fully vested and exercisable.
F4 These options were granted under the 2014 Plan and are fully vested and exercisable
F5 These options were granted on 12/19/19 under the 2014 Plan, with 25% of the shares underlying these options vesting on December 19, 2020 (the one year anniversary of the grant date), and the remainder vesting quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date.
F6 These options were granted on 12/08/20 under the 2014 Plan, with 25% of the shares underlying these options vesting on December 8, 2021 (the one year anniversary of the grant date), and the remainder vesting quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date.
F7 These options were granted on 12/07/21 under the 2014 Plan and vest over four years commencing on the grant date such that 25% vest on the first anniversary of the date of grant and quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date.
F8 These options were granted on 01/02/2022 under the 2014 Plan and vest over three years commencing on the grant date such that 1/3 vest on the first anniversary of the date of grant and then quarterly thereafter for two years, such that they are vested in full on the three-year anniversary of the grant date.

Remarks:

Exhibit 24 - Power of Attorney